TY - JOUR
T1 - MicroRNAs in cancer therapeutics
T2 - " from the bench to the bedside "
AU - Monroig-Bosque, Paloma Del C.
AU - Rivera, Carlos A.
AU - Calin, George A.
N1 - Funding Information:
GA Calin is The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar. Work in Dr. Calin’s laboratory is supported in part by the NIH/NCI grants 1UH2TR00943-01 and 1 R01 CA182905-01, the UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI (P50 CA093459), Aim at Melanoma Foundation and the Miriam and Jim Mulva research funds, the Brain SPORE (2P50CA127001), the Center for Radiation Oncology Research Project, the Center for Cancer Epigenetics Pilot project, a 2014 Knowledge GAP MDACC grant, a CLL Moonshot pilot project, the UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment, a SINF grant in colon cancer, the Laura and John Arnold Foundation, the RGK Foundation and the Estate of C. G. Johnson Jr. P del C Monroig-Bosque receives a research supplement to promote diversity in health related research through grant U54CA096300. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2015/10/3
Y1 - 2015/10/3
N2 - MicroRNAs (miRNAs) are non-coding RNA transcripts that regulate physiological processes by targeting proteins directly. Their involvement in research has been robust, and evidence of their regulative functions has granted them the title: master regulators of the human genome. In cancer, they are considered important therapeutic agents, due to the fact that their aberrant expression contributes to disease development, progression, metastasis, therapeutic response and patient overall survival. This has endeavored fields of biomedical sciences to invest in developing and exploiting miRNA-based therapeutics thoroughly. Herein we highlight relevant ongoing/open clinical trials involving miRNAs and cancer.
AB - MicroRNAs (miRNAs) are non-coding RNA transcripts that regulate physiological processes by targeting proteins directly. Their involvement in research has been robust, and evidence of their regulative functions has granted them the title: master regulators of the human genome. In cancer, they are considered important therapeutic agents, due to the fact that their aberrant expression contributes to disease development, progression, metastasis, therapeutic response and patient overall survival. This has endeavored fields of biomedical sciences to invest in developing and exploiting miRNA-based therapeutics thoroughly. Herein we highlight relevant ongoing/open clinical trials involving miRNAs and cancer.
KW - drug development
KW - microRNA
KW - microRNA-based therapeutics
UR - http://www.scopus.com/inward/record.url?scp=84942035135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942035135&partnerID=8YFLogxK
U2 - 10.1517/14712598.2015.1074999
DO - 10.1517/14712598.2015.1074999
M3 - Review article
C2 - 26372796
AN - SCOPUS:84942035135
SN - 1471-2598
VL - 15
SP - 1381
EP - 1385
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 10
ER -